Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 1/20 | 0.40 |
| ▸ | SLC1A3 | P43003 | 2/20 | 0.33 |
| ▸ | SLC1A2 | P43004 | 2/20 | 0.33 |
| ▸ | SLC1A1 | P43005 | 2/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.32 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.32 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
| ▸ | CNR2 | P34972 | 6/20 | 0.31 |
| ▸ | CNR1 | P21554 | 2/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4704310 | 0.83 | ANPEP (0.40) | SLC1A3SLC1A2SLC1A1MAPTTDP1 | |
| SCHEMBL8062811 | 0.80 | — | — | |
| SCHEMBL24197361 | 0.78 | BRD4 (0.50) | BRD4CYP3A4MAPTCYP2C9CYP2C19 | |
| SCHEMBL2036054 | 0.78 | — | — | |
| SCHEMBL338155 | 0.77 | BRD4 (0.43) | BRD4SLC1A3SLC1A2SLC1A1HSD17B10 | |
| SCHEMBL4698067 | 0.75 | SHBG (0.33) | — | |
| SCHEMBL2478048 | 0.72 | BRD4 (0.42) | BRD4HSD17B10L3MBTL1 | |
| SCHEMBL1967488 | 0.71 | DEGS1 (0.40) | BRD4CYP3A4MAPTCYP2C9CYP2C19 | |
| SCHEMBL21706786 | 0.71 | BRD4 (0.39) | BRD4CYP3A4MAPTCYP2C9CYP2C19 | |
| SCHEMBL1188547 | 0.71 | BRD4 (0.44) | BRD4CYP3A4MAPTCYP2C9CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1385508-B1 | DIPEPTIDYL PEPTIDASE INHIBITORS FOR THE TREATMENT OR PREVENTION OF DIABETES | MERCK & CO INC (US) | 2008-05-21 | — | — | EP | disclosed |
| US-7026316-B2 | Dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes | MERCK & CO., INC. (US) | 2006-04-11 | — | — | US | disclosed |
| US-20040106656-A1 | Dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes | MERCK SHARP & DOHME CORP. | 2004-06-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040106656-A1 | Dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes | DPP4, DPP3, DPP7 | BRD4 1940/4885SLC1A3 1260/4885SLC1A2 1811/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.